View all posts

Global Equity Growth Fund: December 2023

Global equity returns continued to be positive in December with the FTSE All World index (USD) climbing +4.8%. Inflation fell faster than expected in several western economies. This heightened expectations for rapid cuts to central banks’ interest rates during 2024. Mid-month the Federal Reserve’s own policy projections indicated substantial rate cuts to come. With the global Index now just 4% below the all-time end of 2021 high, the fears of “higher for longer” that surrounded the market sell off in the summer seem long forgotten.

The equity market rally has been relatively narrow and dominated by a handful of technology companies. These firms generally continue to enjoy increasing growth forecasts. Such growth is becoming increasingly tricky to find.

One area of the global equity market that has been left behind generally is China. The knock-on impacts of the property sector bust on the domestic economy are relatively well understood. What international investors continue to struggle with, is the gauntlet of regulations and a changing operating environment for companies. A further unanticipated change occurred during December when the country introduced more stringent rules for online gaming companies. While Tencent spokesman indicated they are well positioned to manage the new rules, the violent share price reaction to the news indicated concerns of the investment community. As we wrote last time, multiples are generally low in the country and international investors are generally very underweight in the region. Both, historically, change rapidly once confidence returns.

Trading activity was limited with some reductions in weightings to the energy sector, and top ups made of a few other names. These included adding to Enphase. The renewable energy sector has seen a substantial shift out of favour and we anticipate recovery in sentiment here. A small new position was also added to Puretech, a UK listed American Intellectual Property development company, on the acquisition of Karuna, a firm they set up, by Bristol Myers Squibb. Interestingly Karuna’s new entity filing had been accepted by the Food and Drug Administration (FDA) at the end of November, just two weeks before this announcement, for a 50% premium to their share price. We anticipate feedback from the FDA for fund holding Autolus Therapeutic’s filing which is due in January 2024.

During the month, the Ashburton Global Equity Growth Fund (I class USD) returned +7.8%. The best performing stocks held were Autolus Therapeutics (+50.5%), Enphase (+30.8%) and Align (+28.2%). While the worst were Tencent (-10.2%), Patterson (-7.8%) and Vermilion (-3.6%).

2024 will be another huge year for geopolitics, with a record number of elections being held globally. Inflation remains among the most important variables for investors to watch given it tends to drive the central bank decision makers who raise or lower global liquidity levels and hence investment markets. We continue to look for reasonably priced quality companies who are compounding their intrinsic value and offering above market growth rates.